DENVER, CO – Eon, an AI-powered early detection and care management platform for incidental findings, today announced it has surpassed half a billion radiology reports analyzed, representing the most extensive real-world experience specifically focused on identifying and managing incidental findings in radiology reports. The platform has identified over 2 million patients with incidental findings documented in radiology reports, enabling health systems to coordinate appropriate and timely follow-up.

‍

Incidental findings, unexpected discoveries on imaging studies performed for other reasons, are identified in approximately one-third to 40% of imaging studies, yet 70% of patients never receive appropriate follow-up, according to published research.

‍

"We started our program with Eon in 2018, initially focused on incidental pulmonary nodules, and today we have scaled across 10 disease states and conditions, including most recently breast," said Bartholomew Daugherty, Vice President of Clinical Technology and Systems, Lifepoint Health. "If your hospital or health system isn't managing incidental findings yet, patients are falling through the cracks."

‍

"Our mission is to save lives and give people more tomorrows," said Dr. Akrum (Aki) Al-Zubaidi, Founder and CEO of Eon. "This milestone represents that mission coming to life, transforming half a billion reports into actionable clinical intelligence that helps incidental findings lead to early diagnosis, not missed opportunities."

‍

Founded after Dr. Aki diagnosed a patient with Stage IV lung cancer whose incidental finding had been missed, Eon launched its first lung AI in 2016. Built on proprietary computational linguistics—an AI approach that provides consistent, traceable results—the company has developed specialized AI engines across lung, pancreas, breast, thyroid, kidney, liver, and cardiovascular conditions. In 2020, Eon added expert navigation services to provide dedicated human support alongside its technology platform, enabling health systems to manage patient volumes across multiple disease cohorts and scale across facilities without proportional increases in staffing.

‍

Health systems using Eon report follow-up completion rates on average of over 75% for patients with incidental pulmonary nodules, compared to the national average of approximately 30%. Participating facilities have documented diagnosing the majority of lung cancers in the most treatable Stage I or II phases, with early-stage lung cancer detection rates up to 3x national benchmarks.

‍

“There are people walking about today in the Sarasota community who have lung cancer and don’t even know it,” said Amie Miller, ARNP, Program Leader at Sarasota Memorial Hospital. “Thanks to Eon, we are able to catch more of those lung cancers at an early stage, where it’s curable.”

‍

The half a billion reports milestone comes as Eon rolls out its next-generation Eon 5.0 platform to existing clients and prepares to make it broadly commercially available.

‍

Read more about our journey here.

‍